The association between statin pre-treatment and LDL Levels on the rate of STEMI presentation: data from the ACS Israeli Survey (ACSIS) 2008–2018

Abstract Background ST-elevation myocardial infarction (STEMI) mostly occurs as a result of vulnerable coronary artery plaque rupture. Constituting hypolipidemic and pleiotropic effects, statins stabilize coronary artery plaque and may prevent STEMI events. Purpose To determine the association betwe...

Full description

Saved in:
Bibliographic Details
Published inEuropean heart journal Vol. 41; no. Supplement_2
Main Authors Dadon, Z, Moriel, M, Samuel, T.Y, Steinmetz, Y, Asher, E, Iakobishvili, Z, Glikson, M, Gottlieb, S
Format Journal Article
LanguageEnglish
Published 01.11.2020
Online AccessGet full text

Cover

Loading…
Abstract Abstract Background ST-elevation myocardial infarction (STEMI) mostly occurs as a result of vulnerable coronary artery plaque rupture. Constituting hypolipidemic and pleiotropic effects, statins stabilize coronary artery plaque and may prevent STEMI events. Purpose To determine the association between statin pre-treatment and its intensity, low-density-lipoprotein cholesterol (LDL-C) levels and presentation of patients with an ACS (STEMI vs. NSTEMI/unstable angina [UAP]). Methods Data was drawn from the Acute Coronary Syndrome Israeli Survey (ACSIS), a biennial prospective survey of ACS patients hospitalized in all CCU/Cardiology departments during 2008–2018. The rate of STEMI vs NSTEMI/UAP at the time of presentation was calculated by LDL-C levels on admission, stratified to 5 subgroups (<50, 50–69, 70–100, 101–130 and >130 mg/dl) and the use of statins, including statin intensity prior to the index ACS event. Results Among 5,103 patients, 875 (17%) were pre-treated with high intensity statin (HIST), 1,389 (27%) with low intensity statin (LIST), and 2,839 (56%) were statin naive patients. Statin-pre-treated patients were older, more likely to suffer from co-morbidities and cardiovascular diseases and were more often pre-treated with anti-platelets. The proportion of patients presenting with STEMI vs. NSTEMI/UAP was significantly lower among HIST vs. LIST vs. statin naive patients (31.0%, 37.8%, 54.0%, respectively, p for trend <0.001). At each LDL-C level, the proportion of STEMI was significantly lower among HIST vs. LIST vs. statin naive patients. Multivariate analysis adjusting for pertinent variables including propensity score for statin use, revealed that HIST was independently associated with lower STEMI presentation, but LDL-C<70 and LIST were not. Conclusions Among patients admitted with ACS, pre-treatment with high intensity statin but not LDL-C level, was independently associated with a lower probability of presenting with STEMI. Funding Acknowledgement Type of funding source: None
AbstractList Abstract Background ST-elevation myocardial infarction (STEMI) mostly occurs as a result of vulnerable coronary artery plaque rupture. Constituting hypolipidemic and pleiotropic effects, statins stabilize coronary artery plaque and may prevent STEMI events. Purpose To determine the association between statin pre-treatment and its intensity, low-density-lipoprotein cholesterol (LDL-C) levels and presentation of patients with an ACS (STEMI vs. NSTEMI/unstable angina [UAP]). Methods Data was drawn from the Acute Coronary Syndrome Israeli Survey (ACSIS), a biennial prospective survey of ACS patients hospitalized in all CCU/Cardiology departments during 2008–2018. The rate of STEMI vs NSTEMI/UAP at the time of presentation was calculated by LDL-C levels on admission, stratified to 5 subgroups (<50, 50–69, 70–100, 101–130 and >130 mg/dl) and the use of statins, including statin intensity prior to the index ACS event. Results Among 5,103 patients, 875 (17%) were pre-treated with high intensity statin (HIST), 1,389 (27%) with low intensity statin (LIST), and 2,839 (56%) were statin naive patients. Statin-pre-treated patients were older, more likely to suffer from co-morbidities and cardiovascular diseases and were more often pre-treated with anti-platelets. The proportion of patients presenting with STEMI vs. NSTEMI/UAP was significantly lower among HIST vs. LIST vs. statin naive patients (31.0%, 37.8%, 54.0%, respectively, p for trend <0.001). At each LDL-C level, the proportion of STEMI was significantly lower among HIST vs. LIST vs. statin naive patients. Multivariate analysis adjusting for pertinent variables including propensity score for statin use, revealed that HIST was independently associated with lower STEMI presentation, but LDL-C<70 and LIST were not. Conclusions Among patients admitted with ACS, pre-treatment with high intensity statin but not LDL-C level, was independently associated with a lower probability of presenting with STEMI. Funding Acknowledgement Type of funding source: None
Author Glikson, M
Moriel, M
Gottlieb, S
Iakobishvili, Z
Asher, E
Samuel, T.Y
Dadon, Z
Steinmetz, Y
Author_xml – sequence: 1
  givenname: Z
  surname: Dadon
  fullname: Dadon, Z
  organization: Shaare Zedek Medical Center, Jerusalem, Israel
– sequence: 2
  givenname: M
  surname: Moriel
  fullname: Moriel, M
  organization: Shaare Zedek Medical Center, Jerusalem, Israel
– sequence: 3
  givenname: T.Y
  surname: Samuel
  fullname: Samuel, T.Y
  organization: Shaare Zedek Medical Center, Jerusalem, Israel
– sequence: 4
  givenname: Y
  surname: Steinmetz
  fullname: Steinmetz, Y
  organization: Shaare Zedek Medical Center, Jerusalem, Israel
– sequence: 5
  givenname: E
  surname: Asher
  fullname: Asher, E
  organization: Shaare Zedek Medical Center, Jerusalem, Israel
– sequence: 6
  givenname: Z
  surname: Iakobishvili
  fullname: Iakobishvili, Z
  organization: Clalit Health services, Tel Aviv, Israel
– sequence: 7
  givenname: M
  surname: Glikson
  fullname: Glikson, M
  organization: Shaare Zedek Medical Center, Jerusalem, Israel
– sequence: 8
  givenname: S
  surname: Gottlieb
  fullname: Gottlieb, S
  organization: Shaare Zedek Medical Center, Jerusalem, Israel
BookMark eNotkL1OwzAUhS1UJErhBZjuCEOK7cROwlaVApWCGJKBLbLTazVVm1S2KerGO_QNeRLc0uX-6Zyjq--aDLq-Q0LuGB0zmsePuFw1bahK5Ykcx5TyCzJkgvMol4kYkCFluYikzD6vyLVzK0ppJpkckkO1RFDO9U2rfNt3oNF_I3bgfNg72FqMvEXlN9h5UN0CiucCCtzh2kGQ-2C3yiP0Bspq9j4_OlzQntKeYKG8AmP7zUk5mZYwd1bhuoXyy-5wD_fhNi8fgIePfn8OnLLshlwatXZ4e-4jUr3MqulbVHy8zqeTImoyxiMhTJ6iFCzVzKRCMs24pnyhm4zLOGGKasN0k6BUkjbUCKRhNFSkOjPM5PGI8P_YxvbOWTT11rYbZfc1o_WRan2iWp-p1keq8R-x3m9J
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.1093/ehjci/ehaa946.3002
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1522-9645
ExternalDocumentID 10_1093_ehjci_ehaa946_3002
GroupedDBID ---
-E4
.2P
.I3
.XZ
.ZR
08P
0R~
18M
1TH
29G
2WC
4.4
482
48X
53G
5GY
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAJKP
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAUQX
AAVAP
AAYXX
ABEUO
ABIXL
ABKDP
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFXAL
AFXEN
AGINJ
AGKEF
AGQXC
AGSYK
AGUTN
AHMBA
AHXPO
AIAGR
AIJHB
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APWMN
ATGXG
AXUDD
BAWUL
BAYMD
BCGUY
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CITATION
CS3
CZ4
DAKXR
DIK
DILTD
D~K
E3Z
EBS
EE~
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HZ~
IOX
J21
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M41
M49
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NU-
O9-
OAUYM
OAWHX
OB3
OCZFY
ODMLO
OGROG
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
ROL
ROX
ROZ
RUSNO
RW1
RXO
SEL
TCURE
TEORI
TJX
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZKX
~91
ID FETCH-LOGICAL-c812-55f97e6517b1f7561b12b02dbc826341a0bf1bc4e6a60c0f5e0e6af057b8f1f93
ISSN 0195-668X
IngestDate Thu Sep 12 18:58:09 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue Supplement_2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c812-55f97e6517b1f7561b12b02dbc826341a0bf1bc4e6a60c0f5e0e6af057b8f1f93
ParticipantIDs crossref_primary_10_1093_ehjci_ehaa946_3002
PublicationCentury 2000
PublicationDate 2020-11-01
PublicationDateYYYYMMDD 2020-11-01
PublicationDate_xml – month: 11
  year: 2020
  text: 2020-11-01
  day: 01
PublicationDecade 2020
PublicationTitle European heart journal
PublicationYear 2020
SSID ssj0008616
Score 2.3845901
Snippet Abstract Background ST-elevation myocardial infarction (STEMI) mostly occurs as a result of vulnerable coronary artery plaque rupture. Constituting...
SourceID crossref
SourceType Aggregation Database
Title The association between statin pre-treatment and LDL Levels on the rate of STEMI presentation: data from the ACS Israeli Survey (ACSIS) 2008–2018
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lj9MwEICtaldCXBBP8dYcOICidPOwnYQbWtgHark0SL1FcWprF-22qLQcOPEf9qfwj_aXMGM7aYqKxHKpIje1mswnz8MzHsZe6TjV-M0snHGJDgrPZqFKjAoRlpprIerUnlMw_iRPPvOPUzEdDH71spbWKzVsfuysK_kfqeIYypWqZG8g2W5SHMBrlC9-ooTx859lXG_eb5d0RVVClB2-1OF2Ivno_SgYUZpQu0kQ0EkRtnClRIHQL9piJJvxQfmjvQqUw0lw-m1Z64tzXHCW3222TY6jpxMKLlCOQ5s7kaLGz3dG_amD9iroP56Nk_ueIt0-yXiBPvzFVrh2Ul-u3VA57AzwCXXrvNS2K63XJT6GgQ5r3MUwfFizEKGUtskwaiW_FKObXEh32GS7VvO4x6Tte2qDqFWyUxu4k7L02ZfG8nFW1wWXwzSKko32a3f8_1CKXaqi26RPKztL5eeoUnuA6X6Cqxstq8fTTV5RLm2_3e6RfKUWznFg5zjo_4-eNdQza8q77I73R-Cdg-seG-j5fXZr7DMuHrArZAx6jIFnDBxjsMUYIGOAjIFjDPB25AaIMVgYsIxBn7G3QIQBEWbvRJbAEwaOMHht-XoDRNf1zyvi6iErjz6Uhyehb-QRNjm12hCmyLQUcaZik6HBruJERclMNejbohVVR8rEquFa1jJqIiN0hJcGPQmVm9gU6SO2N1_M9WMGqC64lFmk0U3n0hSKLOQsM8IoI5QonrCgfZ_VV3dcS_V3CT690d3P2O0Nu8_Z3mq51i_QIl2pl5aA33oFims
link.rule.ids 315,783,787,27936,27937
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+association+between+statin+pre-treatment+and+LDL+Levels+on+the+rate+of+STEMI+presentation%3A+data+from+the+ACS+Israeli+Survey+%28ACSIS%29+2008%E2%80%932018&rft.jtitle=European+heart+journal&rft.au=Dadon%2C+Z&rft.au=Moriel%2C+M&rft.au=Samuel%2C+T.Y&rft.au=Steinmetz%2C+Y&rft.date=2020-11-01&rft.issn=0195-668X&rft.eissn=1522-9645&rft.volume=41&rft.issue=Supplement_2&rft_id=info:doi/10.1093%2Fehjci%2Fehaa946.3002&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ehjci_ehaa946_3002
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0195-668X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0195-668X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0195-668X&client=summon